PISCES: A Horoscope for First-Line Targeted Therapy of Metastatic Renal Cell Carcinoma Reply

被引：2

作者：

Escudier, Bernard ^{[1
]}

Porta, Camillo ^{[2
]}

Powles, Thomas ^{[3
,4
]}

Eisen, Tim

Sternberg, Cora N. ^{[5
]}

Mehmud, Faisal ^{[6
]}

Cella, David ^{[7
]}

机构：

[1] Inst Gustave Roussy, Villejuif, France

[2] Fdn Ist Ricovero & Cura Carattere Sci Policlin S, Pavia, Italy

[3] Queen Mary Univ London, Barts Canc Inst, Barts Expt Canc Med Ctr, London, England

[4] Cambridge Univ Hlth Partners, Cambridge, England

[5] San Camillo Forlanini Hosp, Rome, Italy

[6] GlaxoSmithKline, Uxbridge, Middx, England

[7] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 33期

关键词：

TRIAL; PREFERENCE; SUNITINIB; PAZOPANIB; BLIND;

D O I：

10.1200/JCO.2014.57.9219

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

引用

页数：3

共 9 条

[1]

PISCES Trial: The End Does Not Always Justify the Means [J].

Barni, Sandro ;

Petrelli, Fausto .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) :3782-3782

[2]

EVERSUN: A phase II trial of everolimus alternating with sunitinib as first-line therapy for advanced renal cell carcinoma (aRCC) (ANZUP trial 0901) [J].

Davis, Ian D. ;

Long, Anne ;

Martin, Andrew ;

Espinoza, David ;

Yip, Sonia ;

Kichenadasse, Ganessan ;

Thompson, Jennifer F. ;

Harrison, Michelle L. ;

Lowenthal, Raymond M. ;

Pavlakis, Nick ;

Azad, Arun ;

Kannourakis, George ;

Steer, Christopher ;

Goldstein, David ;

Shapiro, Jeremy David ;

Stockler, Martin R. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)

[3]

Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study [J].

Escudier, Bernard ;

Porta, Camillo ;

Bono, Petri ;

Powles, Thomas ;

Eisen, Tim ;

Sternberg, Cora N. ;

Gschwend, Juergen E. ;

De Giorgi, Ugo ;

Parikh, Omi ;

Hawkins, Robert ;

Sevin, Emmanuel ;

Negrier, Sylvie ;

Khan, Sadya ;

Diaz, Jose ;

Redhu, Suman ;

Mehmud, Faisal ;

Cella, David .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (14) :1412-+

[4]

Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition [J].

Holmes, Katherine ;

Roberts, Owain Ll ;

Thomas, Angharad M. ;

Cross, Michael J. .

CELLULAR SIGNALLING, 2007, 19 (10) :2003-2012

[5]

McCann L, 2010, J CLIN ONCOL, V28

[6]

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma [J].

Motzer, Robert J. ;

Hutson, Thomas E. ;

Cella, David ;

Reeves, James ;

Hawkins, Robert ;

Guo, Jun ;

Nathan, Paul ;

Staehler, Michael ;

de Souza, Paul ;

Merchan, Jaime R. ;

Boleti, Ekaterini ;

Fife, Kate ;

Jin, Jie ;

Jones, Robert ;

Uemura, Hirotsugu ;

De Giorgi, Ugo ;

Harmenberg, Ulrika ;

Wang, Jinwan ;

Sternberg, Cora N. ;

Deen, Keith ;

McCann, Lauren ;

Hackshaw, Michelle D. ;

Crescenzo, Rocco ;

Pandite, Lini N. ;

Choueiri, Toni K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :722-731

[7]

PISCES: A Horoscope for First-Line Targeted Therapy of Metastatic Renal Cell Carcinoma [J].

Sun, Maxine ;

Larcher, Alessandro ;

Schiffmann, Jonas ;

Karakiewicz, Pierre I. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (33) :3783-+

[8]

Giving patients a choice improves quality of life: A multi-centre, investigator-blind, randomised, crossover study comparing letrozole with anastrozole [J].

Thomas, R ;

Godward, S ;

Makris, A ;

Bloomfield, D ;

Moody, AM ;

Williams, M .

CLINICAL ONCOLOGY, 2004, 16 (07) :485-491

[9]

A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer [J].

Twelves, C ;

Gollins, S ;

Grieve, R ;

Samuel, L .

ANNALS OF ONCOLOGY, 2006, 17 (02) :239-245

← 1 →